Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
347
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Jacob D. Soumeraia Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Massachusetts General Hospital Cancer Center, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0002-3062-6819View further author information
ORCID Icon,
Andy Nia Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Anna Alperovicha Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Connie Batlevia Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Kurt S. Bantilana Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Thais Fischera Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Amanda R. Copelanda Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Katy Smithc Royal Marsden Hospital, London, UKView further author information
,
Zhitao Yingd Peking University Cancer Hospital, Beijing, ChinaView further author information
,
Anas Younesa Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
&
Andrew D. Zelenetza Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
View further author information
 show all
Pages 2939-2946 | Received 18 May 2020, Accepted 26 Jun 2020, Published online: 15 Jul 2020

References

  • Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med. 1979;90(1):10–13.
  • Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117.
  • Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522.
  • Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet. Oncol. 2014;15(4):424–435.
  • Young RC, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin. Hematol. 1988;25:11–16.
  • Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311(23):1471–1475.
  • Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–1101.
  • Nastoupil LJ, Sinha R, Byrtek M, et al. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172(5):724–734.
  • Federico M, Luminari S, Dondi A, et al. R-CVP Versus R-CHOP Versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–1513.
  • Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet. Oncol. 2016;17(1):57–66.
  • Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
  • Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern cooperative oncology group protocol E4402. J Clin Oncol. 2014;32(28):3096–3102.
  • Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516–2522.
  • Solal-Céligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998;16(7):2332–2338.
  • Pintilie M. Competing risks: a practical perspective. Hoboken (NJ): John Wiley & Sons; 2006.
  • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
  • Fine JP, Jiang H, Chappell R. On semi-competing risks data. Biometrika. 2001;88(4):907–919.
  • Kendall MG. A new measure of rank correlation. Biometrika. 1938;30(1–2):81–93.
  • Therneau T, Ooord J. Expected Survival Based on Hazard Rates Update. 1999.
  • R Core Team. R: A language and environment for statistical computing. Austria: R foundation for statistical computing, Vienna; 2017. https://www.R-project.org.
  • Ardeshna K. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): A preliminary analysis. in ASH Annual Meeting 2010.
  • Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8(4):431–440.
  • Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–1120.
  • Kedmi M, Hedvat CV, Maragulia J, et al. Association of quantitative assessment of the intrafollicular proliferation index with outcome in follicular lymphoma. Br J Haematol. 2014;164(5):646–652.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.